XERS News and Press, Xeris Pharmaceuticals Inc. From 01/10/24

2024-01-10 12:23:55 ET DENVER, Colo., Jan. 10, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Nauticus Robotics (NASDAQ: KITT), Clearmind Medicine Inc (NASDAQ: CMND), SEALSQ Corp (NASDAQ...

2024-01-10 10:13:12 ET DENVER, Colo., Jan. 10, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Clearmind Medicine Inc (NASDAQ: CMND), SEALSQ Corp (NASDAQ: LAES), iCoreConnect Inc (NASDAQ: ICCT), Nvni Grou...

2024-01-10 08:20:42 ET More on Amgen Amgen Inc. (AMGN) Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024 (Transcript) Amgen: Wonderful Stock At Decent Price Amgen: Bet On Its Breakthrough Drug Pharma and biotech deal values spike 35% in 2023: rep...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide license agreement for ...

2024-01-09 01:07:03 ET Summary Xeris Biopharma Holdings focuses on developing and commercializing therapies in endocrinology, neurology, and gastroenterology using their proprietary formulation platforms. Their formulation platforms, XeriSol and XeriJect, address limitations of aq...

2024-01-04 07:17:03 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024 Xeris Biopharma Holdings, Inc. (XERS) Q3 2023 Earnings Call Transcript Xeris Pharmaceuticals GAAP EPS of -$0.09 beats by $0.03, revenue of ...

Company expects to be cashflow positive for the fourth quarter, report total revenue at the high end of its previous guidance of $160M-$165M, and end 2023 with over $72M in cash, cash equivalents, and short-term investments, exceeding its previous guidance of $65M-$70M Company to report Q...

2024-01-01 03:06:21 ET Summary Xeris Biopharma has shown strong revenue growth, from $2.7 million in 2019 to $152.7 million in the 12 months trailing to September 2023. The company's ready-to-use glucagon drug, Gvoke, has the potential for significant sales, especially in the US w...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will pres...

2023-12-18 17:21:05 ET Gainers: Xeris Biopharma Holdings ( XERS ) +4% . Intuitive Machines ( LUNR ) +3% . Century Aluminum Company ( CENX ) +3% . Coherus BioSciences ( CHRS ) +2% . Independent Bank ( INDB ) +2% . Losers: ...